BeOne Medicines FY26 H1 net income climbs to US$464.36 million; revenue rises 32.3% to US$3.22 billion

• BeOne Medicines posted GAAP net income of US$464.36 million, swinging from profit of US$95.59 million a year earlier.
• Total revenue climbed 32.3% to US$3.22 billion; BRUKINSA revenue rose 34.5% to US$2.34 billion.
• Operating income widened to US$574.95 million from US$98.99 million, as gross margin rose 2.9 percentage points to 89.2%.
• On a GAAP basis, diluted earnings per ADS increased to US$4.01 from US$0.85; free cash flow rose to US$595.89 million.
• Recent updates included FDA clearance for TEVIMBRA-based HER2+ GEA regimen, accelerated approval for BEQALZI in R/R MCL, and a Revolution Medicines deal.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260910-12327255), on September 10, 2026, and is solely responsible for the information contained therein.